Mersana Therapeutics Current Ratio 2016-2022 | MRSN
Mersana Therapeutics current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Mersana Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.30B |
$0.09B |
3.38 |
| 2022-06-30 |
$0.24B |
$0.07B |
3.32 |
| 2022-03-31 |
$0.24B |
$0.06B |
4.28 |
| 2021-12-31 |
$0.19B |
$0.05B |
3.98 |
| 2021-09-30 |
$0.20B |
$0.04B |
4.53 |
| 2021-06-30 |
$0.23B |
$0.04B |
5.77 |
| 2021-03-31 |
$0.23B |
$0.04B |
6.64 |
| 2020-12-31 |
$0.26B |
$0.03B |
8.62 |
| 2020-09-30 |
$0.28B |
$0.02B |
13.05 |
| 2020-06-30 |
$0.30B |
$0.02B |
13.15 |
| 2020-03-31 |
$0.08B |
$0.02B |
4.59 |
| 2019-12-31 |
$0.10B |
$0.02B |
4.21 |
| 2019-09-30 |
$0.12B |
$0.02B |
5.12 |
| 2019-06-30 |
$0.13B |
$0.02B |
5.50 |
| 2019-03-31 |
$0.14B |
$0.02B |
6.24 |
| 2018-12-31 |
$0.07B |
$0.07B |
1.07 |
| 2018-09-30 |
$0.09B |
$0.03B |
2.86 |
| 2018-06-30 |
$0.10B |
$0.03B |
3.21 |
| 2018-03-31 |
$0.11B |
$0.03B |
3.80 |
| 2017-12-31 |
$0.12B |
$0.03B |
3.69 |
| 2017-09-30 |
$0.14B |
$0.03B |
5.58 |
| 2017-06-30 |
$0.08B |
$0.03B |
2.53 |
| 2017-03-31 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.00B |
|
0.00 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.646B |
$0.000B |
|
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
|
